Envestnet Asset Management Inc. Has $1.34 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Envestnet Asset Management Inc. lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 162.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,395 shares of the biopharmaceutical company's stock after buying an additional 39,836 shares during the period. Envestnet Asset Management Inc. owned about 0.05% of Catalyst Pharmaceuticals worth $1,344,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock worth $175,957,000 after acquiring an additional 390,116 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock worth $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Boston Partners grew its position in Catalyst Pharmaceuticals by 1.3% in the fourth quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company's stock valued at $27,325,000 after purchasing an additional 16,601 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Catalyst Pharmaceuticals by 6.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company's stock valued at $26,023,000 after buying an additional 79,182 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Catalyst Pharmaceuticals by 80.3% during the 4th quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company's stock worth $15,364,000 after buying an additional 327,936 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Price Performance

CPRX stock opened at $24.28 on Wednesday. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of 20.58, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. The company has a fifty day moving average price of $22.65 and a two-hundred day moving average price of $22.25. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16.

Analyst Upgrades and Downgrades

CPRX has been the subject of several analyst reports. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Bank of America restated a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.